TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02307864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl
Description: Tramadol HCl 50 mg immediate release (IR) tablet administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl
Description: Tramadol HCl 50 mg immediate release (IR) tablet administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl
Description: Tramadol HCl 50 mg immediate release (IR) tablet administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl
Description: Tramadol HCl 50 mg immediate release (IR) tablet administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Description: Moxifloxacin 400 mg tablet administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Description: Moxifloxacin 400 mg tablet administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Description: Moxifloxacin 400 mg tablet administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Description: Moxifloxacin 400 mg tablet administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl Placebo
Description: Placebo matched to tramadol HCl IR tablet administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl Placebo
Description: Placebo matched to tramadol HCl IR tablet administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl Placebo
Description: Placebo matched to tramadol HCl IR tablet administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl Placebo
Description: Placebo matched to tramadol HCl IR tablet administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Placebo matched to Moxifloxacin 400 mg tablet administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Placebo matched to Moxifloxacin 400 mg tablet administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Placebo matched to Moxifloxacin 400 mg tablet administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Placebo matched to Moxifloxacin 400 mg tablet administered orally.
Study: NCT00588510

Intervention type: OTHER
Intervention: Blood draw
Description: Peripheral blood samples (6-9 ml) will be collected in purple top tubes, when routine laboratory tests are being drawn. The blood will be drawn through central venous catheters, whenever possible. Blood will be drawn once from patients with malignant diagnoses other than osteosarcoma, neuroblastoma, Ewing's sarcoma or synovial sarcoma. In patients with osteosarcoma we will obtain blood when baseline laboratory tests are obtained, after every two cycles of treatment (approximately every six weeks), at the end of planned surgery and chemotherapy, every three months for the first year off therapy and yearly thereafter. We will also obtain blood if the patient relapses.
Study: NCT03553095

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal Surgery
Description: Samples will be collected from patient in need of periodontal therapy (surgical procedures i.e. gum surgery, tooth extraction and or dental implant surgery). As standard during this procedures remnant tissue is otherwise discarded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal Surgery
Description: Samples will be collected from patient in need of periodontal therapy (surgical procedures i.e. gum surgery, tooth extraction and or dental implant surgery). As standard during this procedures remnant tissue is otherwise discarded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal Surgery
Description: Samples will be collected from patient in need of periodontal therapy (surgical procedures i.e. gum surgery, tooth extraction and or dental implant surgery). As standard during this procedures remnant tissue is otherwise discarded.
Study: NCT02243865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chordate System S200 + CT100 (active treatment)
Description: Chordate S200 + CT100 (active treatment) gives Kinetic Oscillation Stimulation for 15 minutes to each nostril and by that giving an effect on the autonomic nervous system (ANS).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Chordate System S200 + CT100 (placebo treatment)
Description: Chordate S200 + CT100 (placebo) is used in the same way as Active treatment, but no Kinetic Oscillation Stimulation is given. Catheter is not inflated and no vibration is given.
Study: NCT01522482

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat meal
Description: Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids and fish oil meal
Description: Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats and fish oil.~The dose of fish oils was equivalent to two portions of oily fish.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High unsaturated fat meal
Description: Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for unsaturated fats. It provided a fatty acid profile representative of a typical UK diet.
Study: NCT04026841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody Sintilimab
Description: Patients in experimental group receive the treatment of PD-1 antibody Sintilimab
Study: NCT02608541

Intervention type: OTHER
Intervention: rib fracture fixation
Description: Use of MatrixRib, where indicated, according to departmental protocol

Intervention type: OTHER
Intervention: rib fracture fixation
Description: Use of MatrixRib, where indicated, according to departmental protocol
Study: NCT04437160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin or Pirarubicin
Description: Epirubicin 80-90mg/m2 IV or Pirarubicin 50mg/m2 IV, q21d\*4cycls

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600mg/m2 IV, q21d\*4cycls
Study: NCT03308409

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity extracorporeal shock wave therapy (Li-ESWT)
Description: Low-intensity shock waves are acoustic wavelengths which are transmitted continuously at a frequency between 16 and 20 megahertz for under 10 microseconds. They generate a pressure pulse and transport energy as they propagate through a medium. Three different methods can be used to generate this type of wave: electro-hydraulics, electro-magnetics and piezoelectricity. Regardless of the method, when the shock waves are applied to an organ they interact with the deep tissue. This causes stress and small mechanical traumas, activating the release of angiogenic factors which induce new vascularization of the affected tissue, thereby improving blood flow.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-intensity extracorporeal shock wave therapy (Li-ESWT)
Description: Low-intensity shock waves are acoustic wavelengths which are transmitted continuously at a frequency between 16 and 20 megahertz for under 10 microseconds. They generate a pressure pulse and transport energy as they propagate through a medium. Three different methods can be used to generate this type of wave: electro-hydraulics, electro-magnetics and piezoelectricity. Regardless of the method, when the shock waves are applied to an organ they interact with the deep tissue. This causes stress and small mechanical traumas, activating the release of angiogenic factors which induce new vascularization of the affected tissue, thereby improving blood flow.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-intensity extracorporeal shock wave therapy (Li-ESWT)
Description: Low-intensity shock waves are acoustic wavelengths which are transmitted continuously at a frequency between 16 and 20 megahertz for under 10 microseconds. They generate a pressure pulse and transport energy as they propagate through a medium. Three different methods can be used to generate this type of wave: electro-hydraulics, electro-magnetics and piezoelectricity. Regardless of the method, when the shock waves are applied to an organ they interact with the deep tissue. This causes stress and small mechanical traumas, activating the release of angiogenic factors which induce new vascularization of the affected tissue, thereby improving blood flow.
Study: NCT03718663

Intervention type: OTHER
Intervention: Physiotherapy-guided Evidence-based Exercise Therapy
Description: Standardized supervised exercise therapy for 6-8 weeks (two times per week).

Intervention type: OTHER
Intervention: Part 2: Military training
Description: Part 2: standardized military training for 6-8 weeks in Defence Command Denmark
Study: NCT01387048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: skinoren
Description: gel 15%, twice daily, 36 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: differin
Description: 0.1% gel, once daily in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: skinoren
Description: 12 weeks treatment, the following 24 months only observation
Study: NCT03963752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziyinxiehuo Granules Herbs
Description: 1 pack of Ziyinxiehuo granules Herbs is administered after dissolved, 2 times per day after a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate Tablet
Description: the dose is 6-8mg/d, three times per day after meals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin Acetate 3.75mg Injection
Description: Usage： 80μg/kg by subcutaneous injection, every 4 weeks
Study: NCT00680563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: sc every month (starting dose 1.2 micrograms/kg)
Study: NCT01543386

Intervention type: DRUG
Group type: OTHER
Intervention: Curcumin
Description: The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk
Study: NCT01326195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Dating Violence and HIV Prevention Group
Description: Six, two-hour weekly sessions and one 2-hour booster session 6 weeks later with adolescent females

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-educational Dating Violence and HIV prevention group
Description: Knowledge based intervention matched for time and attention to skills arm
Study: NCT00576433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1000mg iv on days 1 and 15
Study: NCT04001907

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance exercise
Description: effect of exercise and an anabolic agent on body composition, muscle strength, phenylalanine and protein oxidation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: effect of exercise and an anabolic agent on body composition, muscle strength, phenylalanine and protein oxidation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: β-hydroxy-β-methylbutyrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT05009186

Intervention type: OTHER
Group type: OTHER
Intervention: PSA value
Description: We measure PSA value during and after covid-19 infection
Study: NCT04273256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myo-inositol
Description: patients who will be supplemented with 2 grams of Myo-inositol daily for 3 months prior to their in-vitro fertilization cycle
Study: NCT02618824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Histidine Tryptophan Ketoglutarate Solution
Description: Hearts will be arrested with Histidine Tryptophan Ketoglutarate (HTK) solution during cardiac operation. After aortic cross clamp 50-60 ml/kg HTK will be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Histidine Tryptophan Ketoglutarate Solution
Description: Hearts will be arrested with Histidine Tryptophan Ketoglutarate (HTK) solution during cardiac operation. After aortic cross clamp 50-60 ml/kg HTK will be administered

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Terminal Warm Blood Cardioplegia
Description: Terminal warm blood cardioplegia (TWBC) contains 20% HTK solution and 80% blood from cardiopulmonary bypass machine. Before aortic cross clamp removal 10-15 ml/kg TWBC will be administered with temperature 34-36 oCelcius
Study: NCT02636153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: normal diet
Description: Diet containing 1500mg of phosphorus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: restricted phosphate diet
Description: Diet containing 500mg of phosphorus
Study: NCT04062253

Intervention type: DIAGNOSTIC_TEST
Intervention: HCV rapid test
Description: Individuals who test positive for either HIV or HCV are offered PCR (polymerase chain reaction) testing with the xpert technology. Patients with a confirmed active infection are offered delivery and are taken into hospital.

Intervention type: DIAGNOSTIC_TEST
Intervention: HCV rapid test
Description: Individuals who test positive for either HIV or HCV are offered PCR (polymerase chain reaction) testing with the xpert technology. Patients with a confirmed active infection are offered delivery and are taken into hospital.
Study: NCT04228809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: transcranial direct current stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: transcranial direct current stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS
Description: transcranial direct current stimulation
Study: NCT01039025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: After stem cells are collected, Topotecan 3.5 mg/m\^2 intravenously given over 30 minutes on Days 1 - 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: After stem cells are collected, Cyclophosphamide 1 g/m\^2/day intravenously given over 2 hours on Days 1 - 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: After stem cells are collected, Melphalan 70 mg/m\^2/day intravenously given on Days 4 and 5.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cells
Description: On Day 7, some or all of the stem cells will be reinfused.
Study: NCT00179166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPN nutritional supplement
Description: intravenous administration of nutritional supplement for 4 hours at a dosage of 30 kcal/kg/day, in the form of lipids, carbohydrates and protein; the non-protein calories are comprised of lipids (30%) and carbohydrates (70%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPN nutritional supplement
Description: intravenous administration of nutritional supplement for 4 hours at a dosage of 30 kcal/kg/day, in the form of lipids, carbohydrates and protein; the non-protein calories are comprised of lipids (30%) and carbohydrates (70%)
Study: NCT02169180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive ibrutinib capsules 560 milligram (mg) orally, once daily on a 28-day cycle up to 7 cycles or until disease progression (or relapse if the participant achieved a complete response \[CR\]), unacceptable toxicity, or end of treatment, whichever occurs first.
Study: NCT00730431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: IDX184 supplied as size 3, white opaque capsules containing either 5 mg or 25 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: IDX184 supplied as size 3, white opaque capsules containing either 5 mg or 25 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: IDX184 supplied as size 3, white opaque capsules containing either 5 mg or 25 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: IDX184 supplied as size 3, white opaque capsules containing either 5 mg or 25 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: IDX184 supplied as size 3, white opaque capsules containing either 5 mg or 25 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: IDX184 supplied as size 3, white opaque capsules containing either 5 mg or 25 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplied as size 3, white opaque capsules matching IDX184 capsules.
Study: NCT01883986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care
Description: Care delivered by a nurse including symptom assessment and management, patient education on lung cancer and treatment options , discussion and communication about preferences for care, psychosocial assessment including referrals to ancillary services such as social services and spiritual care as requested by the patient.
Study: NCT02674191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mini-plates supported molar intrusion
Description: (Stryker, Leibinger, GmbH\& Co., Freiburg, Germany) for molar intrusion using miniplates to treat hyperdivergent adolescence

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of ULTRACARE benzocaine 20%,
Description: topical anesthesia (Ultradent Products, Inc)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Administration of , Mepivacaine-l
Description: local anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BETADINE povidone-iodine 10%
Description: a local disinfectant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (150g Clindamycin/tds) for 1 week
Description: Postoperative antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Cataflam 25mg), are prescribed post-operatively
Description: an analgesic
Study: NCT01217216

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group-based Intervention
Description: compared effects of a group-based intervention on weight loss and physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-based Intervention
Description: compared telephone-based intervention to weight loss and physical activity.
Study: NCT03510988

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hybrid breast FDG PET/MRI
Description: Hybrid breast FDG PET/MRI
Study: NCT03552861

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation(rTMS)
Description: Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation(rTMS)
Description: Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation(rTMS)
Description: Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation(rTMS)
Description: Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
Study: NCT00822354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Subjects will be randomized to receive either tadalafil for the first month followed by placebo or placebo for the first month and followed by tadalafil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Subjects will be randomized to receive either tadalafil for the first month followed by placebo or placebo for the first month and followed by tadalafil